百克生物：三价流感病毒裂解疫苗（BK-01佐剂）临床试验申请获得批准

Core Viewpoint - Baike Biological has received approval from the National Medical Products Administration for its trivalent influenza virus split vaccine (BK-01 adjuvant) clinical trial [2] Group 1 - The company announced the receipt of the clinical trial approval notice on the evening of October 13 [2] - The approval is significant for the development of the trivalent influenza vaccine, indicating progress in the company's research and development efforts [2]